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Abstract: Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have pro-
duced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people 
over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older indi-
viduals are now physically more active than their forebears and travel more widely. This provides a greater opportunity 
for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to 
infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a 
state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater de-
cline in their immune response than others. In this review we have sought to consider who are the ‘at risk’ individuals, 
how they might best be treated and when. 
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INTRODUCTION 
 The world is going grey. In less than ten years there will 
be more individuals over the age of 65 than children under 
the age of 5, for the first time in history. A recent report 
revealed that the estimated increase in the population over 65 
between July 2007 and July 2008 was more than 10.4 mil-
lion people, an average of 870,000 each month [1]. If we 
restrict our view to Europe the shift in the demographic pro-
file of the population in the last 60 years has been considera-
ble. In 1950, young people outnumbered older individuals by 
a ratio of more than 3:1, with about 143 million people under 
the age of 14 and almost 45 million people over the age of 
65. Medical advances and the improvement in social condi-
tions in Europe have resulted in a steady increase in lifespan 
which has almost doubled in the last 160 years [2]. This, in 
conjunction with the decline in the birth rate, has produced a 
population whose demographic profile is skewed towards 
older individuals. Within the next 40 years the European 
Rural Development Project [3] suggests that the ratio of 
young: old (under 14:over 65) will have altered to 1:2 in 
2050 (compared to 3:1 in 1950), and those over the age of 65 
will constitute almost 28% of the overall population in Eu-
rope.  
 The optimism created by an increased life expectancy is 
countered by the reality of the health care burden produced 
by an ageing population. Human ageing is not only inextri-
cably linked with a plethora of co-morbid conditions but is 
also associated with diminished resistance to common infec-
tions, as a consequence of immunosenescence. Immunose  
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nescence has been defined as “the age-associated decrease in 
immune competence that renders individuals more suscepti-
ble to diseases and increases morbidity and mortality due to 
infections and a variety of other age-related pathologies” [4]. 
If we want to couple a longer lifespan with healthy ageing, it 
is imperative to be able to identify the degree of susceptibil-
ity, and also to develop intervention strategies to reduce the 
effects of immunosenescence. The focus of this review, is to 
explore the means by which we could identify those individ-
uals “Who” are at risk of accelerated immunosenescence, 
“How” intervention could be administered and “When” 
would be an appropriate time of intervention. 
WHO? 
 Epidemiological surveys and clinical observations reveal 
an increase in the prevalence and severity of infection with 
advancing age [5,6], whilst laboratory tests confirm a decline 
in immune function. Clinicians recognise that older individ-
uals often have difficulty in dealing with previously encoun-
tered pathogens resulting in the reactivation of otherwise 
latent pathogens such as the herpes viruses, herpes zoster [7] 
and cytomegalovirus [8]. Furthermore, increases in the prev-
alence of infection in the elderly range from three-fold for 
community acquired pneumonia to twenty-fold for urinary 
tract infections. There is also an increased frequency of nos-
ocomial bacterial infections, in part due to greater institu-
tionalisation rates [9]. The increased susceptibility of older 
individuals to infection is coupled with progression to more 
severe illness rather than recovery. For example, in the 
young infection with influenza is typically followed by a 
contagious illness of 1-2 weeks duration with full recovery, 
but in the elderly infection is often associated with consider-
able morbidity and mortality [5]. For influenza, vaccination 
with inactivated virus is the most common approach to pre-
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vention, with an annual review of the antigenic composition 
of the vaccine to match the most prevalent strains [6,10]. 
However the efficacy of the vaccine, defined as the percent-
age reduction in attack rates between vaccinated and unvac-
cinated populations, is affected by age. Efficacy of the influ-
enza vaccine is expected to be between 70-90% in young 
individuals but is considerably reduced to between 30-40% 
in those over the age of 65 [6, 11-13]. A similar story exists 
with Hepatitis B where an antibody titre of anti‐HBs level 
10 IU/L following vaccination provides protection [14]. 
Comparing efficacy of hepatitis B vaccination between 
healthy elderly individuals (average age 74) versus young 
control group (average age 28), all of the young individuals 
developed a protective response, compared with only 42% of 
the elderly cohort [15]. Failure of the immune system to 
provide protection to the body is not only related to factors 
such as co-morbid conditions, nutritional status (nutrients 
and/or protein-energy malnutrition and obesity) and hormo-
nal pathway dysregulation, but also age itself.  
 As described above, vaccination studies reveal that older 
individuals, even healthy ones, are more prone to develop 
vaccine preventable diseases such as influenza, hepatitis B 
and pneumonia, and this cannot be ascribed to reduced vac-
cination coverage [9,16] or vaccine inadequacy. The most 
likely, and currently most recognised cause of vaccine fail-
ure, is dysfunctional immunity in the elderly. The lifelong re-
shaping and adaptation of the immune system in response to 
a plethora of pathogenic challenges, as well as cellular and 
molecular changes, are believed to result in this dysfunction-
al immunity. A further factor may be chronic low-grade 
inflammation in the elderly due to co-morbid conditions. The 
degree to which these changes occur and when they occur 
within an individual’s lifetime is poorly understood. There-
fore the manifestation of dysfunctional immunity or 
immunosenescence between individuals will vary considera-
bly, as will the response to immune intervention. Hence 
measurements are needed to provide an estimation of an 
individual’s degree of immune competency or incompetency. 
Owing to the complexity of factors giving rise to 
immunosenescence it is unlikely that a single predictor will 
be adequate. Instead, a selection of parameters could provide 
an evaluation of an individual’s immunosenescence status, 
against which the efficacy of immune intervention therapies 
could be tested. 
Assessing Immunosenescence 
 A number of studies have described methods for identify-
ing and measuring immune competency in older individuals. 
The earliest arose following the need to classify elderly sub-
jects “Senior Europeans” or “SENIEUR Protocol” for strict 
admission criteria, in order to make meaningful laboratory 
cross-comparisons in the evaluation of healthy aged people 
and immune parameters. Consideration of patient medical 
conditions and on-going prophylactic intervention resulted in 
a further classification of so-called “non-SENIEURs” indi-
viduals or frail elderly [17]. As the vast majority of elderly 
fall into the latter group, and these are the individuals that 
would benefit most from immune intervention therapies, 
further characterization of these individuals could help iden-
tify at-risk groups and intervention strategies.  
Immune Risk Phenotype and Inflamm-aging 
 The pioneering OCTO and NONA studies were aimed at 
identifying factors predicting 2, 4 and 6 year mortality rates 
and have resulted in the emerging concept of an Immune 
Risk Profile (IRP) [18-20]. The IRP defined from healthy 
octogenarians and nonagenarians, characteristically display 
(i) high levels of CD8+ and low level of CD4+ T-cells (an 
inverted CD4+:CD8+ ratio), (ii) an increase in the number of 
dysfunctional terminally differentiated memory T-cells 
(CD8+CD28-) and (iii) the depletion in the number of naïve T 
and B-cells, as well as (iv) cytomegalovirus (CMV) 
seropositivity and large increases in the number of 
CD8+CD28-CD57+ T-cells, known to be associated with 
CMV status [21].  
 The complex remodeling of the immune system during 
ageing includes a profound modification within the cytokine 
network. The typical features of this phenomenon are a gen-
eral increase in plasma cytokine levels and a chronic low-
grade pro-inflammatory condition named inflamm-aging 
[22,23]. This results due to the shift from a CD4+ T-helper 
cell TH1-like cytokine response to a TH2-like response, and 
furthermore from an increase in levels of pro-inflammatory 
cytokines (i.e. interleukin-6 (IL-6), Tumor necrosis factor 
(TNFα), as well as IL-1β, IL-18, and IL-12). A wide range of 
other factors have also been claimed to contribute to this 
low-grade inflammatory state, including increased amount of 
fat tissue, decreased production of sex steroid and chronic 
co-morbid conditions (e.g. diabetes and chronic heart dis-
ease) [4]. In addition, this altered inflammatory response has 
also been attributed to continuous exposure to external 
stressors such as chronic CMV antigen stimulation, and/or 
reactive oxygen species, leading to a progressive activation 
of macrophages and related cells in most organs and tissues 
of the body [21]. This is likely to be the most important 
cause of inflamm-aging that, in association with the genetic 
background of the individual, potentially triggers the onset of 
the most important age-related diseases, such as atheroscle-
rosis, metabolic syndrome, insulin-resistance and diabetes 
mellitus, Alzheimer’s disease, arthritis, osteoporosis, and 
two complex age-associated syndromes that are sarcopenia 
and frailty [16,24]. 
Thymic Output 
 One of the major features of human immunosenescence 
is involution of the thymus which is the key site for T cell 
development and maturation [25]. Thymic atrophy is charac-
terized by a progressive, age-related size reduction in and 
profound changes in its anatomy caused by the loss of thym-
ic epithelial cells and replacement of thymocytes with adipo-
cytes. The resulting impairment in thymopoiesis is a key 
contributory factor in the reduction of naïve T-cells in aged 
individuals [4,26]. Studies tracking changes in thymic output 
have attempted to establish the number of circulating naïve 
cells and thereby provide an assessment of immune status. 
This was first achieved in immunocompromised HIV pa-
tients undergoing highly active antiretroviral therapy 
(HAART) [27], using an excisional by-product of T cell 
receptor (TCR) gene rearrangement, known as TREC (T-cell 
receptor excision circle) [28]. TREC estimation has subse-
quently been utilized not only as a measure of biological 
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ageing but also as a tool for predicting immune senescence 
status within the ageing population [26, 29].  
 The immunological parameters identified from the pio-
neering Swedish OCTO and NONA longitudinal studies 
provide a robust set of criteria for the determination of an 
individual’s immunological status. However, these criteria 
may require fine tuning, since the increased mortality risk 
profile exhibited in individuals 65 and over does not neces-
sarily translate through to individuals assessed in their mid 
50’s [18]. Therefore further studies are required with a 
broader demographic and a wider geographical net in order 
to discover biomarkers that are identifiable earlier in life, so 
that intervention strategies can be administered sooner rather 
than later. 
HOW? 
 Since thymic atrophy is a preceding event in all cases of 
immunosenescence, different ways have been investigated to 
rejuvenate the peripheral T cell pool, to delay or even reverse 
the senescence of the immune system caused by thymic 
atrophy and immunosenescence. The vast majority of these 
studies have been performed in mouse models, and interpre-
tation of those studies that were performed with human sub-
jects are generally complicated by the pathology of cancer or 
transplantation. Whilst these examples are invaluable in 
providing a proof of concept, in many instances they are far 
from being directly applicable to rejuvenation of the waning 
immune system in ageing humans. Nevertheless, the follow-
ing is an exploratory overview of several reported strategies 
which are categorized into the three R’s of Rejuvenation: 
Restoration, Replacement and Reprogramming.  
Restoration 
 This approach is based on the use of cytokines, hor-
mones, and growth factors known to play a role in the 
maintenance of a normal thymic microenvironment with the 
aim of restoring a functional cellular milieu. Some of these 
agents have already been evaluated in clinical trials, even 
though it is not yet clear whether they can restore 
thymopoiesis to healthy and durable levels. In fact, the min-
imum degree of ‘rejuvenation’ of the thymus required in 
order to obtain a significant clinical response has yet to be 
determined. 
 One of the first approaches developed was sex steroid 
ablation, as these hormones are known to negatively regulate 
T cell development by inducing thymic involution. In mice, 
prepubescent castration has been shown to prevent thymic 
atrophy, while post-pubescent castration is thought to reverse 
thymic atrophy and to augment thymic output [30]. Sex 
steroid ablation has been successfully tested in a clinical trial 
with the LHRH (lutenising hormone releasing hormone) 
agonist goserelin after autologous and allogeneic 
haemopoietic stem cell transplant (HSCT). This treatment 
was reported to induce strong CD4 T cell regeneration, along 
with a more varied TCR repertoire and enhanced peripheral 
T cell activity [30, 31].  
 Growth hormones are also known to play a role in T cell 
development. There are data showing that aged humans have 
lower serum levels of Growth hormone (GH) and Insulin-
like growth factor (IGF-1) [32]. GH is produced by the pitui-
tary gland and may also be generated in a variety of 
haemopoietic cells [33]. GH receptors are expressed on 
thymocytes and peripheral T cells [34]. Concordantly, it has 
been demonstrated that the administration of GH or IGF-1 
can enhance T cell recovery in different experimental condi-
tions such as syngeneic and allogeneic HSCT recipients, 
ageing mice, and ageing bone marrow transplantation (BMT) 
murine recipients [35]. Interestingly, although GH effects are 
mainly mediated by IGF-1, it has been observed that these 
effects would be orchestrated in part by the direct action of 
GH [32]. However IGF-1 seems to directly modulate 
thymocyte development and it is believed to induce IL-7 and 
stem cell factor (SCF) production by thymic epithelial cells 
(TECs) [32]. Along with GH and IGF-1, the peptide hor-
mone ghrelin, principally known to induce GH by binding 
through the growth hormone secretagogue receptor (GHS-
R), has been reported to enhance thymopoiesis in aged mice 
[36]. In addition, ghrelin is able to repress inflamm-aging, 
that in turn would contribute to the enhanced T cell reconsti-
tution observed in older mice [37].  
 Keratinocyte growth factor (KGF), also called fibroblast 
growth factor 7 (FGF-7), regulates the proliferation and 
differentiation of epithelial cells, including TECs, by acting 
through the KGF receptor FGFR2IIIb [38] within the thymus 
where it is normally released by thymic fibroblasts and de-
veloping thymocytes [39]. KGF is able to protect the thymus 
from damage and to boost thymopoiesis in young and old 
mice. In the latter case, it has been found to improve 
thymocyte numbers, thymic architecture, and T cell function 
[40], and its administration in combination with sex steroid 
blockade has also been successful [39, 41]. Similar results 
have been obtained with the administration of nerve growth 
factor (NGF) in aged mice [42]. Presently, clinical trials are 
in progress to evaluate the ability of KGF administration to 
promote the reconstitution of thymopoiesis after allogeneic 
HSCT.  
 IL-7 is a γ-chain cytokine produced by stromal cells in 
the thymus, and plays a pivotal role in supporting thymocyte 
development, as well as peripheral T cell survival and prolif-
eration [43]. It is believed that reduction in the intra-thymic 
IL-7 level is critical in the process of age associated thymic 
atrophy [44]. Several studies in both animal models and 
humans have been carried out. The reversion of age-
associated thymic atrophy and concomitant enhanced 
thymopoiesis and thymic output has been demonstrated in 
old mice treated with exogenous IL-7 [45]. Moreover, a 
study in old female rhesus macaques treated with IL-7 prior 
to vaccination with influenza A/PR/8/34 (H1N1) virus would 
endorse IL-7 administration as an adjuvant to enhance vac-
cine responsiveness in the elderly [46]. These results have 
been extended to clinical trials. Recombinant IL-7 adminis-
tered to humans with metastatic cancer has proven to be safe 
and effective, where an IL-7 dependent expansion of CD4 
and CD8 T cells with a concomitant reduction in the per-
centage of regulatory T cells was observed [47]. In another 
clinical study with patients with non-hematologic cancers 
who received IL-7 administration, the expanded circulating 
T cells were found to exhibit a broad TCR repertoire [48]. 
Finally, although IL-12 levels are not decreased in ageing 
animals, in vitro stimulation of thymocytes with IL-7 togeth-
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er with IL-12 induced a synergistic enhancement of cell 
proliferation [49], suggesting that IL-12 administration may 
contribute toward the retardation or even reversal of thymic 
involution in elderly individuals.  
 An adequate intake of both vitamins and trace elements 
are required for the immune system to function optimally 
[50]. In the elderly, a deficiency of these nutrients may lead 
to suppressed immunity, which in turn could predispose 
individuals to infections and further progress 
immunosenescence. In fact, compounds that possess anti-
oxidant properties could be useful for the rejuvenation of the 
thymus, such as those contained in the leaves of Ginkgo 
biloba [51]. In many studies zinc supplementation has been 
proposed to be potentially useful in counteracting thymic 
ageing. Zinc deficiency induces age-independent thymic 
atrophy [52] while its supplementation increases thymic 
cellularity and possibly thymopoiesis [53], responsiveness to 
vaccines [54] and thymulin secretion [55] in aged individu-
als. In spite of all these data, overall results regarding zinc 
supplementation are still controversial [56]. A comparison of 
a number of existing clinical studies by El Kadiki et al con-
cluded that there is no definitive evidence to recommend the 
routine use of multivitamin and/or mineral dietary supple-
mentation to reduce infections in the elderly [57]. However 
this contradiction may be explained by the variable degree of 
micronutrient deficiency between individuals. Whilst the 
healthy ageing population, who generally have no nutritional 
deficit, exhibit changes in T cell subsets because of the high-
er amount of pathogen recognition over the years, the elderly 
population with signs of under nutrition or even protein 
energy malnutrition (PEM) display eroded immune functions 
of both the adaptive and innate arm. This condition frequent 
in the institutionalized elderly population [58], is the cause 
of recurrent infections, and can be partially reversed by in-
creasing food intake unless an inflammatory process is pre-
sent [59, 60].  
Replacement 
 The strategies of immune system “replacement” devel-
oped to date encompass the adoptive transfer and the ex vivo 
generation of T cells.  
 Adoptive transfer procedures have been used in the 
HSCT setting to reduce the incidence of viral reactivation in 
immunosuppressed post-transplantation and cancer patients. 
Cobbold and colleagues described the infusion of antigen 
specific lymphocytes directed against viruses which cause 
chronic infections, such as CMV. Direct donor isolation of 
CMV-specific CD8+ T cells is achieved using magnetic 
beads conjugated to HLA-peptide tetramers directed to one 
epitope of the CMV viral envelope protein, pp65. Tests in 
patients following HSCT were non-toxic and, importantly, 
relatively low doses (of between 1.2 x 104 and 2 x 106 lym-
phocytes) were sufficient to control and prevent viral reacti-
vation [61].  
 Another example of adoptive transfer which has been 
used in the treatment of cancer involves the use of artificial 
antigen presenting cells (aAPCs). The in vitro induction and 
expansion of these cells over successive rounds of stimula-
tion results in the generation of therapeutically high levels of 
antigen-specific cytotoxic T lymphocytes (CTL) [62]. In 
parallel with HSCT, the ageing immune system has a re-
duced ability to effectively combat recurrent and newly ac-
quired infections [63, 64]. Lifelong latent infection with 
CMV has been reported to drive the exhaustion of the im-
mune system through the reduction of the naïve T cell reper-
toire and the disproportionate expansion of CMV-specific 
CD8+ memory T cell pool, which results in a reduction in 
memory pool diversity [21]. CMV infection has been associ-
ated with increased mortality in the very elderly [8], and 
frailty [65], therefore therapies for the treatment of chronic 
CMV infection are of great interest. It remains to be seen if 
the encouraging results obtained in the HSCT setting could 
be replicated in elderly individuals to prolong their immuno-
logical competency at the point where immunosurveillance 
against CMV reactivation is defective. Progress in the devel-
opment of artificial antigen presenting cells may herald a 
means of rejuvenating components of the innate immune 
system. 
 An alternative and possibly more valid approach for 
replacing immune function lost with ageing is in vitro T cell 
development. Xenosystems such as fetal thymic organ cul-
tures (FTOC); reaggregate thymic organ cultures (RTOC) 
and thymic stromal cell monolayer cultures (TSMC), have 
provided knowledge about T cell differentiation and positive 
and negative selection processes [66]. Importantly the TSMC 
system consists of OP9 mouse bone marrow stromal cells 
transduced to overexpress either the Delta Notch ligand Dll-
1 or Dll-4 [67, 68]. This system has definitively demonstrat-
ed that the induction of T cells, and a simultaneous block in 
B cell lineage potential, depends on Delta ligand Notch sig-
naling [69]. However, systems based on the use of cells 
cultured as a monolayer fail to push T cell differentiation 
over the double positive stage [70]. A very promising ap-
proach to produce terminally differentiated T cells relies on 
the use of 3-dimensional matrix structures to recreate the 
cellular microenvironment of the thymus. Using autologous 
stem cells, this method would be able to generate T cells 
which have successfully undergone both positive and nega-
tive selection in vitro. The resultant naive T cell population 
would have a diverse repertoire and should be able to be 
transferred into patients with defective thymopoiesis, such as 
aged individuals. An initial study based on this technique has 
shown that T cells can be generated from bone marrow stem 
cells in vitro using a 3-dimensional scaffold seeded with skin 
fibroblasts and keratinocytes. The authors were able to re-
produce a thymic microenvironment equivalent, and the 
mature T cells produced exhibited rearrangement of the 
TCRβ and TCRα genes, with expression of a diverse antigen 
receptor repertoire [71]. This discovery opens up the possi-
bility of generating new T cells in vitro from host skin and 
stem cells, with the benefit of being efficiently and safely 
injected back into the host in the absence of graft versus host 
disease, whilst responses to antigen would also be self re-
stricted.  
Reprogramming 
 Finally and probably the most “revolutionary” treatment 
of immunosenescence could be based on reprogramming the 
ageing immune system. It has been demonstrated that there 
exists a correlation between telomere length and limited 
division potential. To date, there is general consensus that 
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telomeres represent an inherent biological clock [72]. There-
fore, restoring telomere length could significantly extend 
cellular lifespan [73], and this would be possible by regulat-
ing telomeres through the activity of telomerases, enzymes 
required in order to maintain telomere length and stability. 
Some recent papers have described the successful extension 
of the replicative lifespan of T cells through the ectopic ex-
pression of telomerase catalytic subunit (hTERT) [74]. With 
the implemetation of such a method it would be possible to 
collect, rejuvenate and re-introduce antigen specific lympho-
cytes from older individuals, with the aim of prolonging and 
enhancing a specific immune response in aged individuals.  
 Once an elderly individual has been identified as exhibit-
ing signs of immunosenscence, a difficult problem in itself, 
the choice of how to improve their immunity has then to be 
made. Immune restoration therapies are unlikely to be a 
“one-off” treatment, but will have to be repeated. A critical 
factor in any treatment regime is compliance, which in turn 
is dependent on dose efficacy, safety, frequency, and route of 
delivery. Clearly any treatment administered either orally or 
by inhalation will be much preferred to one which depends 
on multiple injections.  
WHEN? 
 The problem of defining immunosenescence and decid-
ing whether to implement therapeutic intervention is ex-
tremely complex. One current hypothesis is that it is similar 
to defining frailty in older individuals [75]. One broad defi-
nition of frailty was through equating frailty to the degree of 
functional dependence in daily living [76]. While it is easy to 
identify individuals who are dependent on others for issues 
of daily living, this is not useful as a single clear identifying 
factor. The approach used by Rockwood et al over a number 
of years has been to associate frailty with an accumulation of 
deficits [77, 78]. In this approach an index of frailty was 
constructed by counting the deficits that people accumulated. 
Although the deficits could be individually weighted, the 
authors chose to treat all characteristics equally even though 
some, for example cancer, carry a higher risk of mortality 
than others, such as skin disorders. The results revealed that 
the probability of an adverse event was related in a dose 
dependent fashion to the accumulation of deficits [79]. We 
propose that a similar approach could be used to define 
immunosenescence. Based on this assumption, we could use 
an accumulation of immune deficits to predict immune status 
and decide whether to implement therapeutic intervention 
(Fig. 1). Before we discuss this further, let us consider the 
justification of this approach.  
 In complex systems such as the immune system, reliabil-
ity is dependent in part on the quality of the components and 
also on any functional overlap. Thus reliability in the face of 
possible component failure can be achieved by having re-
dundancy within the system, which should ensure that whilst 
some components fail, the system as a whole remains func-
tional. In any system where there is redundancy one would 
not expect there to be a single component whose failure 
leads to complete system failure. Thus it is with the immune 
system.  
 Immunosenescence is a multifaceted phenomenon en-
compassing several complex changes affecting both the 
innate and adaptive branches of the immune system [2-4]. 
Whereas the exact mechanisms leading to 
immunosenescence are still poorly understood, immune 
system failure is unlikely to come from a single deficit but 
probably arises from an accumulation of defects in different 
components within the system. The question is which com-
ponents and the magnitude of the deficits. To answer this we 
could produce a larger number of parameters all known to 
alter with age. Such a list could include: thymic involution 
measured through assessing thymic output; the degree of 
chronic antigenic stimulation; signal transduction changes in 
the immune cells; protein-energy malnutrition; reduction in 
the repertoire; changes in cell phenotype profiles; alteration 
in the number of regulatory T cells; increases in the number 
of cells with a senescent phenotype; reduction in the num-
bers of naïve B or T cells, poor in vitro proliferative respons-
es; the presence of large clones of B cells (BMGUS) or en-
larged clones of T cells; and infection either with persistent 
 
Fig. (1). The accumulation deficits concept applied to immunosenescence. 
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viruses such as herpes or bacteria such as Mycobacterium 
tuberculosis, Helicobacter pylori or members of Salmonella 
species. Our idea would be that when an individual is posi-
tive for a number of these parameters, they may be consid-
ered to be showing an immunosenescent phenotype, and as a 
consequence, for example, be unable to respond adequately 
to vaccination. Such a model proves a testable hypothesis to 
approach the difficult clinical definition of 
immunosenescence.  
CONCLUSION 
 Despite growing evidence that changes in the respon-
siveness of the immune system with age lead to an increased 
susceptibility to various age-related diseases, poorer re-
sponse to vaccination and increased incidence of infectious 
diseases, the problem of defining immunosenescence and 
how to implement therapeutic intervention still remains an 
unresolved challenge. This review demonstrates that the 
achievement of an accurate assessment of an 
immunosenescent phenotype remains fraught with clinical 
and biological difficulties. Immunosenescence, although 
complex, is undoubtedly a real and important condition af-
fecting healthy ageing. Hence methods for identifying and 
measuring immunosenescence and understanding its implica-
tions justify further evaluation and development. Strategies 
for enhancing immune capacity either through the preven-
tion, retardation or rejuvenation of the immune system are 
currently still largely addressed in animal models, which 
may or may not be pertinent to humans. Thus, complemen-
tary clinical and translational studies at the epidemiological, 
clinical, cellular, molecular and genetic levels are needed to 
elucidate the complexity of immunosenescence in the ageing 
human population. In view of the functional interplay be-
tween different components of the immune system, future 
approaches designed for human beings should probably 
combine two or more immune targets in studies to impart 
greater insight into the best way of promoting immune reju-
venation. Further studies are essential in order to achieve the 
restoration of immunity in the elderly, with the aim of in-
creasing the capacity of older individuals to protect against 
infections and delay the onset and severity of age-related 
diseases. 
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